TO: Dr. Roy Vagelos‚ Chairman and CEO Merck Corporation. January‚ 1991. The decision to move forward with the program to donate the new drug Mectizan on a large scale to the affected population in the Third World needs to be systematically analyzed. There are two especially important angles from which this decision needs to be considered. The first concern that needs to be taken into account is that of the stockholders and investors in this company‚ whose interests you are ultimately charged with
Premium Medicine Pharmacology Pharmacy
the drug in 2004 due to heart attacks c) Merck’s knowledge of the effects of Vioxx and unethical decision to continue to sell the drug 2) Vigor Study d) Vioxx lessened stomach bleeding e) Results also showed higher risk of heart attacks f) Merck blamed naproxen for skewing the results against Vioxx 3) New England Journal of Medicine Omission g) Merck omits three heart attacks from article submission h) Inclusion of omitted data caused a significantly
Premium Coronary artery disease Aspirin Hypertension
Analysis on Merck: Conflict and change Assessment: Merck is one of the biggest pharmaceutical companies in the world today. Although encountered with success‚ it still faces many problems today while trying to be the market leader competing against its competition. While being research and development driven company‚ Merck now has to go beyond R&D to stay competitive in the pharmaceutical industry. The main issue that seems to come
Premium Pharmaceutical industry Pharmacology
Questions for the Merck Case Create a decision tree for Merck. The 2 leftmost branches would identify the alternatives related to licensing Davarink (specifically license versus not to license). Next‚ if Merck decides to pursue license‚ they go into phase I which results in a success‚ or failure. Phase I success is followed by phase II where Merck has the opportunity to develop the drug to treat depression alone‚ weight loss alone‚ or both‚ or contemplate phase II failure. Finally phase
Premium Decision tree Decision theory
Pharmaceuticals: Merck Sustaining Long-term Advantage Through Information Technology Hiroshi Amari Working Paper No. 161 Working Paper Series Center on Japanese Economy and Business Columbia Business School December 1998 Columbia-Yale Project: Use of Software to Achieve Competitive Advantage PHARMACEUTICALS: MERCK Sustaining Long-term Advantage Through Information Technology Prepared by Hiroshi Amari Research Associate‚ Yale University William V. Rapp and Hugh T. Patrick Co-principal
Premium Clinical trial Pharmaceutical industry Drug development
including Bayer AG and Novartis are exploring a deal for Merck & Co Inc’s consumer healthcare business‚ as they seek to gain scale in a fragmented industry‚ according to several people familiar with the matter. Reckitt Benckiser Group PLC and Procter & Gamble Co are also among the parties that have held discussions with Merck about buying the unit‚ best known for Coppertone sunscreen and Claritin allergy medicine‚ the sources said this week. The Merck business‚ which also includes Dr. Scholl’s foot
Premium Pharmacology Marketing Pharmacy
Executive Summary Merck & Company has been presented with an opportunity to invest $30 million for the purchasing rights of an obesity and high cholesterol lowering drug‚ KL-798 from Kappa Labs. Based on the expected probabilities of success through each product-development phase for this new drug‚ as well as the costs involved‚ the net present value of the project is -$1.16 million and is therefore recommended that Merck passes on the investment. Sensitivity analysis also show that adjusting
Premium Clinical trial Net present value Investment
c. Moody’s Investors Service downgraded the long-term senior unsecured rating of AZN from A1 to Aa2 in 2007. Assess any potential association between this downgrade and AZN’s arrangements with Merck. Paris‚ July 30‚ 2007 -- Moody’s Investors Service downgraded the long-term senior unsecured ratings of AstraZeneca plc and its guaranteed subsidiary to A1 from Aa2. This downgrade followed the announcement of AstraZeneca’s acquisition of MedImmune for a total consideration of more than US$15 billion
Premium Money
Merck was at the top of the pharmaceutical market for many years. The company made substantial profits almost every year. Not only were they a company that made money but they also made their financial gains in an ethical manor. Fourton magazine even named them the “most admired” company. But in 2004‚ the company would be faced with major challenges that would threaten to end the company’s existence. Their once best selling painkiller Viol had been recalled by the federal government because the drug
Premium Pharmacology Pharmaceutical industry
EXECUTIVE SUMMARY Statement of the Problem Merck & Co.‚ Inc.‚ a leading pharmaceutical company‚ faces the threat of the patents of its most popular drugs expiring in 2002. The only way to counter the loss of sales from these drugs going off patent is to develop new drugs in order to refresh the company’s portfolio. LAB Pharmaceuticals‚ a small pharmaceutical company who specializes in the treatment of neurological disorders‚ has approached Merck with the opportunity to license Davanrik‚ a new
Premium Patent Pharmacology Pharmaceutical drug